Saurabh Saha M.D. Ph.D. is Chief Executive Officer and a member of the Board of Directors of Univations Pharma. Most recently, as Senior Vice President of R&D at Bristol Myers Squibb, Dr. Saha led translational medicine across all therapeutic areas spanning discovery, early development through late development and commercialization. In 2019, he led the R&D diligence in the acquisition of Celgene by BMS and subsequently managed key aspects of the integration across both organizations. During his tenure, he lay the foundation for the BMS R&D headquarters in Cambridge MA, serving as site head and establishing a research focus on discovering new cancer treatments for immunotherapy resistance.
Previously, Dr. Saha was a venture partner at Atlas Venture where he held leadership positions with a number of its portfolio biotech companies, including as chief medical officer of Synlogic, and as chief executive officer of Delinia until its sale to Celgene in early 2017. In 2008, Dr. Saha established the translational research and development organization at BioMed Valley Discoveries where he served as chief scientific officer and later president, and was responsible for leading the development and demonstrating human effectiveness of two first-in-class cancer therapies. Earlier in his career, Dr. Saha was a management consultant in the pharmaceutical practice at McKinsey & Company and subsequently appointed director and head of the New Indications Discovery Unit at Novartis. Dr. Saha is on the editorial boards of a number of medical journals and is an associate member and global clinical scholar at Harvard Medical School.